Evidence map›Paper›PMID 42690018›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Broad-Spectrum, Cell Envelope-Active Marinocyclin Antibiotics From a Coral-Derived Bacterium Are Effective Against Colistin-Resistant Bacteria.

Clara Chepkirui, Sandra Silva, Jan Straetener, Chandrashekhar Padhi, Tina Keller-Costa, Tess Lamer, Laura Reinke, Heike Brötz-Oesterhelt, Rodrigo Costa, Jörn Piel

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Clara ChepkiruiInstitute of Microbiology, Eidgenössische Technische Hochschule (ETH) Zürich, Zurich, Switzerland.
Sandra SilvaiBB - Institute for Bioengineering and Biosciences and i4HB - Institute for Health and Bioeconomy, Instituto Superior Técnico, Lisbon, Portugal.ORCID https://orcid.org/0000-0002-4763-0662
Jan StraetenerInterfaculty Institute of Microbiology and Infection Medicine, Microbial Bioactive Compounds, University of Tübingen, Tübingen, Germany.
Chandrashekhar PadhiInstitute of Microbiology, Eidgenössische Technische Hochschule (ETH) Zürich, Zurich, Switzerland.
Tina Keller-CostaiBB - Institute for Bioengineering and Biosciences and i4HB - Institute for Health and Bioeconomy, Instituto Superior Técnico, Lisbon, Portugal.
Tess LamerInstitute of Microbiology, Eidgenössische Technische Hochschule (ETH) Zürich, Zurich, Switzerland.
Laura ReinkeInterfaculty Institute of Microbiology and Infection Medicine, Microbial Bioactive Compounds, University of Tübingen, Tübingen, Germany.
Heike Brötz-OesterheltInterfaculty Institute of Microbiology and Infection Medicine, Microbial Bioactive Compounds, University of Tübingen, Tübingen, Germany.ORCID https://orcid.org/0000-0001-9364-1832
Rodrigo CostaiBB - Institute for Bioengineering and Biosciences and i4HB - Institute for Health and Bioeconomy, Instituto Superior Técnico, Lisbon, Portugal.
Jörn PielInstitute of Microbiology, Eidgenössische Technische Hochschule (ETH) Zürich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-2282-8154

Funding

Antimicrobial Resistance 407240_167051Cluster of Excellence EXC2124European Union's Horizon 2020 101000392Funding Scheme 5 - Capitalization and Business Innovation of the Portuguese Recovery and Resilience Plan C644915664-00000026"Fundo Azul" Programme of the Ministry of the Sea FA_05_2017_032German Center for Infection Research TTU 09.833Portuguese Foundation for Science and Technology LA/P/0140/2020Portuguese Foundation for Science and Technology UIDB/04565/2020Promedica Foundation 1-001369-000Swiss National Science Foundation 205320_219638Swiss National Science Foundation "NRP72" (407240_167051)
6 · The paper itself

Abstract

The marine bacterial genus Aquimarina comprises diverse members with numerous natural product biosynthetic gene clusters but few characterized compounds. Here we report a novel class of lipopeptides with exceptional antibiotic activity, named marinocyclins, isolated from Aquimarina megaterium EL43 associated with the octocoral Eunicella labiata. The major congener marinocyclin A exhibited potent and uniform activity against a broad panel of drug-resistant gram-negative and gram-positive pathogens, including ESKAPE bacteria. The natural product efficiently compromised the outer and inner bacterial membranes, leading to rapid cell permeabilization and lysis. This activity profile was mediated by the ability to bind lipopolysaccharides, anionic phospholipids enriched in bacterial membranes, and peptidoglycan precursors. Eukaryotic cytotoxicity required higher doses than antibacterial activity. Genomic data suggest a nonribosomal biosynthetic origin for marinocyclins. These findings position marinocyclins as a promising new scaffold for antibiotic development and highlight the potential of Aquimarina spp. as a source of novel antibiotics. Further medicinal chemistry optimization of marinocyclins could enhance their prokaryotic selectivity to generate leads for treating infections caused by drug-resistant pathogens.

Indexed as

AnthozoaAnti-Bacterial AgentsColistinDrug Resistance, BacterialGram-Negative BacteriaGram-Positive BacteriaLipopeptidesAnimalsCell MembraneMicrobial Sensitivity TestsAnti-Bacterial AgentsColistinLipopeptidesantibacterial activityantibioticsbiologymicrobiologynatural productpeptidoglycan

Identifiers

PMID42690018
PMCPMC13676389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.